Welcome to our dedicated page for BioAge Labs SEC filings (Ticker: BIOA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioAge Labs, Inc. filings document a clinical-stage biopharmaceutical issuer developing therapeutic candidates tied to human aging biology. The company's 8-K reports record periodic financial results, Regulation FD clinical updates for BGE-102, and disclosure of NLRP3 and APJ program development.
Other filings describe capital actions and governance, including common stock offering agreements under shelf registration statements, use-of-proceeds categories for research, clinical development, manufacturing and general corporate purposes, annual meeting proxy matters, director elections, auditor ratification, and board recommendations. These records also frame the company's capital structure and public-company reporting obligations.
BioAge Labs, Inc. is offering $75,000,000 of its common stock in a primary public offering under an effective shelf registration, with underwriters holding a 30-day option to buy up to an additional $11,250,000 of shares. The company’s stock trades on the Nasdaq Global Select Market under the symbol “BIOA.” BioAge is a clinical-stage biopharmaceutical company focused on metabolic diseases such as obesity, led by BGE-102, an orally available, brain-penetrant NLRP3 inhibitor now in a Phase 1 SAD/MAD trial, and APJ agonist programs targeting obesity with oral and injectable candidates. As of December 31, 2025, BioAge preliminarily estimates $285.1 million in cash, cash equivalents and marketable securities, and currently expects existing cash plus offering proceeds to fund operations and capital needs through 2029. Net proceeds are intended mainly for research, clinical and manufacturing activities for BGE-102 and the NLRP3 and APJ programs, as well as working capital and general corporate purposes.
BioAge Labs, Inc. is offering $75,000,000 of its common stock in a primary public offering under an effective shelf registration, with underwriters holding a 30-day option to buy up to an additional $11,250,000 of shares. The company’s stock trades on the Nasdaq Global Select Market under the symbol “BIOA.” BioAge is a clinical-stage biopharmaceutical company focused on metabolic diseases such as obesity, led by BGE-102, an orally available, brain-penetrant NLRP3 inhibitor now in a Phase 1 SAD/MAD trial, and APJ agonist programs targeting obesity with oral and injectable candidates. As of December 31, 2025, BioAge preliminarily estimates $285.1 million in cash, cash equivalents and marketable securities, and currently expects existing cash plus offering proceeds to fund operations and capital needs through 2029. Net proceeds are intended mainly for research, clinical and manufacturing activities for BGE-102 and the NLRP3 and APJ programs, as well as working capital and general corporate purposes.
BioAge Labs, Inc. filed a current report describing an indication expansion for its oral NLRP3 inhibitor BGE-102 and outlining upcoming clinical milestones. The company plans to start a Phase 1b/2a proof-of-concept trial in patients with diabetic macular edema (DME) in mid-2026.
In a preclinical DME model, oral BGE-102 showed dose-dependent preservation of retinal vascular integrity, with near-complete protection from vascular leakage and up to 90% preservation of microvascular integrity. BGE-102 has shown favorable tolerability to date in an ongoing Phase 1 trial, alongside robust reductions in inflammatory biomarkers such as hsCRP, IL-6, and IL-1β.
The development plan includes completing the Phase 1 trial with full data in the first half of 2026, starting a Phase 2a proof-of-concept trial in obesity with cardiovascular risk factors in the first half of 2026, initiating the DME Phase 1b/2a trial in mid-2026, and targeting data readouts for the cardiovascular trial in the second half of 2026 and for the DME trial in mid-2027.
BioAge Labs, Inc. filed a current report describing an indication expansion for its oral NLRP3 inhibitor BGE-102 and outlining upcoming clinical milestones. The company plans to start a Phase 1b/2a proof-of-concept trial in patients with diabetic macular edema (DME) in mid-2026.
In a preclinical DME model, oral BGE-102 showed dose-dependent preservation of retinal vascular integrity, with near-complete protection from vascular leakage and up to 90% preservation of microvascular integrity. BGE-102 has shown favorable tolerability to date in an ongoing Phase 1 trial, alongside robust reductions in inflammatory biomarkers such as hsCRP, IL-6, and IL-1β.
The development plan includes completing the Phase 1 trial with full data in the first half of 2026, starting a Phase 2a proof-of-concept trial in obesity with cardiovascular risk factors in the first half of 2026, initiating the DME Phase 1b/2a trial in mid-2026, and targeting data readouts for the cardiovascular trial in the second half of 2026 and for the DME trial in mid-2027.
BioAge Labs, Inc. Chief Financial Officer Dov A. Goldstein reported an option exercise and related share sales. On 01/13/2026 he exercised a stock option for 27,000 shares of common stock at an exercise price of $8.39 per share, increasing his directly held common stock to 49,408 shares and leaving 92,587 stock options beneficially owned.
On the same date, he sold an aggregate of 27,000 common shares in multiple transactions at weighted average prices of $18.4278, $19.4526, $20.5392 and $21.0808 per share, leaving 22,408 common shares beneficially owned directly. The filing notes these trades were executed pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2024, and that the option vests in 1/48th monthly installments beginning May 17, 2024, with an early exercise feature.
BioAge Labs, Inc. Chief Executive Officer and director Kristen Fortney reported selling 233,107 shares of the company’s common stock on January 13, 2026. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on November 21, 2024, which is designed to allow insiders to systematically trade shares over time.
The shares were sold at a weighted average price of $18.1163 per share, with individual sale prices ranging from $18.00 to $18.385 per share. After this transaction, Fortney beneficially owns 976,949 shares of BioAge Labs common stock in direct ownership.
A holder of BioAge Labs, Inc. common stock has filed a notice under Rule 144 to sell 233,107 shares of common stock through Raymond James & Associates on the NASDAQ, with an approximate sale date of 01/13/2026. The filing lists an aggregate market value of these planned sales of $4,195,926.00 and states that 35,855,037 shares of the issuer’s common stock are outstanding.
The shares to be sold relate to a prior restricted stock purchase dated 08/14/2015, when 1,210,056 common shares were acquired from BioAge Labs, Inc. and paid for by check. By signing the notice, the person for whose account the securities are to be sold represents that they do not know of any material adverse information about the issuer’s operations that has not been publicly disclosed.
BIOA filed a Form 144 notice for a planned sale of 27,000 shares of its common stock. The shares are to be sold through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate market value of $531,828.03. The filing notes that 35,855,037 shares of the issuer’s common stock are outstanding. The 27,000 shares were acquired on 01/13/2026 through the cash exercise of an option that was granted on 04/17/2024.
BioAge Labs, Inc. reported additional positive interim Phase 1 results for BGE-102, a novel brain-penetrant NLRP3 inhibitor being tested in people with obesity and elevated cardiovascular risk. In the first multiple ascending dose cohort, participants receiving 120 mg once daily showed rapid and marked anti-inflammatory effects, including an 86% reduction in hsCRP at Day 14, with 93% of participants reaching normalized hsCRP levels below 2 mg/L.
BGE-102 also produced significant reductions in IL-6 and fibrinogen, two biomarkers linked to systemic inflammation and cardiovascular events, and was described as well tolerated with a favorable safety profile. The company highlighted a newly issued patent covering additional composition of matter and a novel NLRP3 binding site. Planned milestones include completing the Phase 1 trial and initiating a Phase 2a proof-of-concept study in the first half of 2026, followed by Phase 2a data in the second half of 2026.
BioAge Labs, Inc. Chief Medical Officer Paul D. Rubin reported option exercises and a share sale. On January 2, 2026, he exercised stock options to acquire 5,433 common shares at $4.11 per share and 2,000 common shares at $6.57 per share. On the same day he sold 7,433 common shares at a weighted average price of $12.8468 per share, with individual sale prices ranging from $12.571 to $13.242. Following these transactions, he directly held no shares of common stock but continued to hold stock options, including 16,303 options at $4.11 and 7,383 options at $6.57. The activity was carried out under a Rule 10b5-1 trading plan adopted on November 5, 2024.
BioAge Labs' Chief Medical Officer reported an insider transaction involving 18,000 shares of common stock on December 9, 2025. The officer exercised stock options to buy 18,000 shares at $6.57 per share and then sold the same 18,000 shares at $12 per share, resulting in no directly held common stock after the sale.
The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 5, 2024. Following the exercise, the officer continues to hold 9,383 stock options with a $6.57 exercise price, which vest in 1/48th monthly installments that began on April 1, 2022, and have an expiration date of May 28, 2032.
BioAge Labs (BIOA) reported Q3 results showing initial collaboration revenue and strong liquidity as it advances metabolic disease programs. Collaboration revenue was $2.1 million in the quarter and $5.9 million year‑to‑date, driven by its Novartis agreement. Operating expenses were $25.2 million, leading to a net loss of $20.2 million and net loss per share of $0.56.
BioAge ended the quarter with $215.6 million in cash and cash equivalents and $295.6 million in total cash, cash equivalents, and marketable securities, and stated this is sufficient to fund planned operations at least one year after issuance of the statements. Deferred revenue was $8.1 million, reflecting ongoing work under the Novartis collaboration.
Subsequent to quarter‑end, the company filed a shelf registration permitting offerings of up to $250.0 million and entered an at‑the‑market Sales Agreement with Leerink Partners for up to $75.0 million in common stock, with a commission rate of up to 3.0%. As of October 31, 2025, shares outstanding were 35,855,037.